Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Company will leverage its proprietary vIgDTM platform using directed evolution to create novel, multi‐functional first in class immunotherapies
SEATTLE, Wash., June 13, 2016 – Alpine Immune Sciences, Inc., (AIS), a privately held biotechnology company developing a next‐generation immune system modulation platform, today announced the closing of its $48 million Series A financing round.
The financing was led by OrbiMed Advisors, a leading investment firm focused on the healthcare sector, alongside additional investors including Frazier Healthcare Partners and Alpine BioVentures. Alpine BioVentures was responsible for the seed funding and founding of Alpine Immune Sciences.
Mitchell H. Gold, M.D., Managing Partner at Alpine BioVentures, will serve as AIS’ Executive Chairman and acting Chief Executive Officer. Jay Venkatesan, M.D., Managing Partner at Alpine BioVentures, will be President and a member of the board of directors. They will be joined on the board of directors by Jamie Topper, M.D., Ph.D., Managing General Partner of Frazier Healthcare Partner’s Life Sciences team and Peter Thompson, M.D., Private Equity Partner with OrbiMed Advisors.
“We are honored this experienced group of investors recognizes the tremendous potential existing at Alpine Immune Sciences. AIS is taking a unique approach to modulating the immune system through the directed evolution of naturally occurring ligands – creating the next generation of cancer and autoimmune therapeutics with our vIgDTM platform,” said Mitchell H, Gold, M.D., Alpine Immune Sciences’ Executive Chairman and acting CEO. “We believe this significant funding, along with our collective expertise, will enable us to discover and develop clinically meaningful and transformative therapies for patients.”
“Alpine Immune Sciences’ ability to attract some of the industry’s leaders in immunotherapy, combined with its technology platform, creates an opportunity to move beyond current approaches to modulating the immune system. AIS is unique in its ability to impact multiple immune system interactions simultaneously at the critical junction of cellular communication known as the ’Immune Synapse’,” said Peter Thompson, M.D., Private Equity Partner with OrbiMed Advisors. “I look forward to working with the team at Alpine to make a difference in the lives of patients with cancer, autoimmune conditions, and other serious diseases.”
About Alpine Immune Sciences
Alpine Immune Sciences (AIS) was founded in 2015 and seed funded by Alpine BioVentures. AIS is focused on developing novel protein‐based immunotherapies using its proprietary variant immunoglobulin domain (vIgDTM) platform technology. The vIgDTM platform, unlike other